DUBLIN, September 20, 2021--(BUSINESS WIRE)--The "The Corporate Reputation of Pharma in 2020 during the Covid-19 Pandemic - the Perspective of UK Patient Groups" report has been added to ResearchAndMarkets.com's offering.
The results of an independent survey of 97 UK patient groups in 2020. Collectively, these patient groups reached out to 70,400 UK patients during 2020. The respondent UK patient groups commented on 17 companies, selecting those with the "Best" corporate reputation in 2020, and assessing which were "Best" at tackling Covid-19 during 2020.
About the 2020 'Corporate Reputation' Survey
A survey of 97 UK patient groups
When? The survey was conducted in November 2020-February 2021, when key events of the pandemic will have influenced the opinions of respondent UK patient groups.
The questionnaire? Pharma was assessed across a wide range of its activities important to patients and patient groups, including a new indicator for 2020 - pharma's effectiveness at tackling Covid-19.
Companies assessed? 17 companies were included in the 2020 UK analyses:
AbbVie, Astellas, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, GSK, Janssen, Merck & Co/MSD, Novartis, Pfizer, Roche, Sanofi and Takeda/Shire.
How were the companies assessed?
The indicators used to measure a company's corporate reputation:
1. Covid-19 response [new for the 2020 survey]
2. Patient centricity
3. Patient information
4. Patient safety
5. High-quality products
6.i. Transparency: pricing
6.ii. Transparency: clinical-trial data
6.iii. Transparency: funding of external stakeholders
8. Quality of relationships with patient groups
9. Providing services 'beyond the pill'
10.i. Engaging patients in research
10.ii. Engaging patients in development.
Summary of Findings
Patient groups responding to 2020's 'Corporate Reputation of Pharma' survey are uniquely positioned to comment on the pharma industry's performance during the pandemic, as patient organisations not only understand the perceptions of patients, but are also the only stakeholder to network with ALL other stakeholders in the healthcare system.
For this reason, the analyst collected (November 2020-February 2021) the opinions of 97 UK patient groups on the performance of the pharmaceutical industry during the Covid-19 pandemic of 2020.
UK patient-group perspectives on pharma during the Covid-19 pandemic: top-line findings
1. The pharma industry's effectiveness at tackling Covid-19 in the UK in 2020. According to the feedback provided by 2020's respondent UK patient groups, patients in the UK faced many new challenges during the pandemic. So, during 2020 and beyond, UK patient groups looked to pharma for extra support in helping the patients with whom they were familiar.
The 2020 'Corporate Reputation' survey found that 74% of 2020's respondent UK patient groups judged the industry's response to Covid-19 to be "Very effective" or "Effective" - one of the highest figures reported for Western Europe. Despite the high score, however, UK patient groups thought that the pharma industry could have done more for patients during the Covid-19 pandemic.
2. The pharma industry's corporate reputation in the UK in 2020. Respondent UK patient groups rated the pharma industry's corporate reputation more favourably in 2020 than in 2019. In 2020, 42% of 2020's respondent UK patient groups stated that the industry had an "Excellent" or "Good" corporate reputation, against 33% saying the same in 2019.
3. Rankings of individual pharma companies for...
Response in the UK to Covid-19 in 2020 (out of 17 pharma companies). The three companies voted "Best" in 2020 for helping UK patients and patient groups during Covid-19 were: 1st, Pfizer 2nd, AstraZeneca and, 3rd, Janssen - as assessed by respondent UK patient groups familiar with the company.
Overall corporate reputation in the UK in 2020 (out of 17 pharma companies). The three companies voted "Best" for overall corporate reputation in the UK in 2020 were: 1st, Pfizer, 2nd, Boehringer Ingelheim and, 3rd, AstraZeneca - as assessed by respondent UK patient groups familiar with the company.
The commentaries supplied to the analyst by the respondent UK patient groups made clear that their opinions on pharma companies during 2020 were primarily influenced by company responses to Covid19 - whether that be development and production of vaccines, or (seen as particularly important by UK patient groups) other efforts by companies to support patients during lockdown.
Key Topics Covered:
UK patient-group relationships with pharma
Corporate-reputation rankings of 17 pharma companies, 2020 (v. 2019) assessed by UK patient groups familiar with the companies
Corporate-reputation rankings of 4 pharma companies, 2020 assessed by UK patient groups that work/partner with the companies
Profiles of the 17 companies, 2020 (v. 2019)
I Profiles of respondent UK patient groups, 2020
II List of respondent UK patient groups that wished to be attributed, 2020
III What respondent UK patient groups say about pharma (and how the industry can improve), 2020/2021
Bristol Myers Squibb
Merck & Co/MSD
For more information about this report visit https://www.researchandmarkets.com/r/t51hm7
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005638/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900